# CONFERENCE PROGRAMME




## Brno Oncology Days Nursing Conference 2026

9–11 September 2026 | Brno, Exhibition Centre, Hall E

ESMO

Masaryk Memorial Cancer Institute

www.onkologickedny.cz/en

## NETWORKING BRINGS PROFFESIONALS TOGETHER

Join us in Brno and network with your colleagues, interact with key opinion leaders, ask questions and debate on burning topics in the field of medical oncology in a uniquely meaningful way.

**SEE YOU AT BOD 2027**
**13–15 OCTOBER 2027**

# CONTENT


Introduction ..... 2
Conference plan ..... 4

**CONFERENCE PROGRAMME ..... 6**

**WEDNESDAY / J. BAKEŠ HALL ..... 7**
Brno Oncology Days – 50 years ..... 7

**THURSDAY / J. BAKEŠ HALL ..... 7**
International Brno Oncology Days ..... 7
Future Directions in Personalized Neoadjuvant Treatment ..... 7
Precision Medicine ..... 7
Breaking News 2025 ..... 8

**FRIDAY / J. BAKEŠ HALL ..... 9**
International Brno Oncology Days ..... 9
Cancer Survivorship – Life after Cancer ..... 9
Breast Cancer ..... 9
Case Reports ..... 9

**INVITED SPEAKERS**
Rupert Bartsch ..... 11
Andrés Cervantes ..... 12
Elisa Fontana ..... 13
Nadia Harbeck ..... 14
Jakub Kucharz ..... 15
Cord Langner ..... 16
Elena Rohleder ..... 17
Andreas von Deimling ..... 18
Elizabeth Smyth ..... 19
Other important foreign speakers ..... 20

# INTRODUCTION

*"For fifty years, Brno Oncology Days has brought together experts who collectively shape modern cancer care in the Czech Republic."*

Dear colleagues and friends,

We are delighted and honoured to welcome you to Brno for **the 50th anniversary edition of Brno Oncology Days** and **the 40th Nursing Conference**.

The fifty-year history of Brno Oncology Days reflects not only the long tradition of this professional gathering, but also the remarkable progress in oncology – from the dawn of modern treatment approaches to the current era of immunotherapy, targeted therapies and precision medicine. Since its inception, Brno Oncology Days has sought to bring together experts from across disciplines to explore new ways of improving care for people with cancer. Half a century later, this purpose remains as important as ever.

Over the years, Brno Oncology Days has evolved into the Czech Republic's largest forum for professionals across the full spectrum of cancer care. For five decades, it has fostered connections between clinical practice, research and education while promoting interdisciplinary collaboration. The open exchange of experience and a shared commitment to finding the best possible solutions are key reasons why the conference continues to hold a unique place among professional events in the Czech Republic.

This anniversary programme highlights both the breadth of contemporary oncology and its rapid evolution. It begins with the traditional multidisciplinary **Glio Meeting** on brain tumours, followed by specialist sessions covering individual cancer types as well as broader themes in modern cancer care. Discussions will address the latest developments in systemic therapy, radiotherapy, surgery, molecular diagnostics, prevention, and supportive and palliative care, alongside the use of healthcare data and artificial intelligence in oncology. Particular attention will also be given to the care of adolescents and young adults, hereditary cancers, the centralisation of cancer care and other current challenges in our field.

**The Nursing Conference** continues to be an integral part of the congress, offering a programme focused on current issues in specialised nursing care, clinical research and interdisciplinary collaboration, complemented by practical workshops. The programme will also feature the traditional **Laboratory Diagnostics in Oncology** conference, the patient programme and **the Psycho-Oncology Conference**, with the latter focusing this year on parenthood in the context of cancer.
We are delighted to welcome the sixth edition of the **International Brno Oncology Days (IBOD)** as part of the congress, further strengthening international collaboration through lectures by leading experts from abroad and discussions on the latest developments in cancer diagnosis and treatment.
Another returning highlight is the popular **ONKO Cinema**, a unique educational format combining recordings of diagnostic and therapeutic procedures with expert commentary and discussion.

We are grateful that the conference is once again held under the auspices of **the European Society for Medical Oncology (ESMO)**, **the Czech Society for Oncology**, and other professional societies

that have long supported the development of oncology in the Czech Republic.

As we celebrate the 50th edition, we would like to thank everyone who has helped shape this remarkable tradition over the past half-century – organisers, speakers, participants, partners and supporters. Their dedication has made Brno Oncology Days not only a highly respected professional forum, but also a place where new collaborations and friendships begin.

Finally, we are grateful to all our partners, sponsors and exhibitors, whose support makes a conference of this scale possible.

May the 50th anniversary edition of Brno Oncology Days bring fresh insights, inspiring discussions and valuable opportunities to forge new partnerships, share experiences and contribute to advancing care for people with cancer.

We look forward to seeing you in Brno.

**Assoc. Prof. Radka Lordick Obermannová, MD, PhD**
Chair of the BOD Programme Committee

**Tereza Malá, MBA**
Chair of the Nursing Conference Programme Committee

**Prof. Marek Svoboda, MD, PhD**
General Director of the Masaryk Memorial Cancer Institute

# BRNO EXHIBITION CENTRE



BRNO, KŘÍŽKOVSKÉHO, PAVILON E →


Premium Snack Bar
ONKO cinema
J. Švejda Hall
MMCI
Press center
NEBÝT NA TO SAMA z. s.
ELISABETH PHARMACON, spol. s r.o.
Nemocnice Jihlava, příspěvková organizace
LIV´beauty s.r.o.
2ND FLOOR
L. Bakešová Hall
Slide room
Internet point
Premium Snack Bar
R. Werner Hall
J. Šprindrich Hall
J. Bakeš Hall
1ST FLOOR
Lounge S3, S4
Nursing workshop S2
Lounge S1
Workshop information center
Partners section
Poster section (LCD display)
Relax zone
Corporate materials of partners
Coffee Break
ENTRANCE →
Registration, attendance confirmation
Partners section
Lunches
GROUND FLOOR

# CONFERENCE PROGRAMME

| | J. Bakeš Hall |
|---|---|
| Wednesday 9 September 2026 | **International Brno Oncology Days** |
| 14:00–15:30 | Brno Oncology Days – 50 years * |
| | |
| Thursday 10 September 2026 | **International Brno Oncology Days** |
| 9:50–11:20 | Future Directions in Personalized Neoadjuvant Treatment * |
| 12:30–13:30 | LUNCH |
| 13:30–15:00 | Precision Medicine * |
| 15:00–15:10 | COFFEE BREAK |
| 15:10–16:40 | Breaking News 2026 |
| 18:30–24:00 | **GALA DINNER** |
| | |
| Friday 11 September 2026 | **International Brno Oncology Days** |
| 8:00–9:30 | Cancer Survivorship – Life after Cancer * |
| 9:30–9:50 | COFFEE BREAK |
| 9:50–11:20 | Breast Cancer * |
| 11:20–11:30 | BREAK |
| 11:30–13:00 | Case Reports |
| 13:00–13:30 | LUNCH |

*Simultaneous interpretation is provided in this session.

## Wednesday 9 September

**14:00–15:30** **BRNO ONCOLOGY DAYS – 50 YEARS ***
Moderators: R. Lordick Obermannová, I. Kiss
Chairs: J. Halámková, A. Cervantes (Brno, Valencia)

14:00 1. **FIFTY YEARS OF PROGRESS IN ONCOLOGY: FROM EMPIRICAL TREATMENT STRATEGIES TO PRECISION MEDICINE**
A. Cervantes (Valencia)

14:25 2. **FIFTY YEARS OF CZECH ONCOLOGY: FROM PIONEERING CARE TO FUTURE INNOVATION**
I. Kiss, M. Svoboda (Brno)

14:50 3. **THE FUTURE OF CANCER PREVENTION: INTEGRATING SCREENING, RISK PREDICTION AND AI**
J. Halámková (Brno)

15:15 Closing

*Simultaneous interpretation is provided in this session.

## Thursday 10 September

**09:50–11:20** **IBOD FUTURE DIRECTIONS IN PERSONALIZED NEOADJUVANT TREATMENT ***
Moderators: R. Lordick Obermannová, F. Lordick
Chairs: C. Langner, E. Smyth, M. Liberko, J. Tomášek, A. Ryška, M. Vočka (Graz, Oxford, Prague, Brno, Hradec Králové)

09:50 67. **PREDICTIVE BIOMARKERS IN GI ONCOLOGY: FROM PATHOLOGY TO PERSONALISED TREATMENT**
C. Langner (Graz)

10:05 68. **FUTURE DIRECTIONS IN PERSONALISED NEOADJUVANT TREATMENT OF OESOPHAGOGASTRIC ADENOCARCINOMA**
E. Smyth (Oxford)

10:20 69. **PERSONALISED THERAPY IN PANCREATIC CANCER: WHERE DO WE STAND?**
M. Liberko (Prague)

10:35 70. **FROM METASTATIC TO NEOADJUVANT: TRANSLATING PRECISION THERAPY IN COLORECTAL CANCER**
J. Tomášek (Brno)

10:50 Panel discussion

11:20 Break

**13:30–15:00** **IBOD PRECISION MEDICINE ***
Moderator: P. Grell
Chairs: E. Rohleder, O. Slabý, A. Ryška, S. John, J. Fínek (Berlin, Brno, Hradec Králové, Pilsen)

13:30 74. **LIQUID BIOPSY (CTDNA): PATHOLOGIST'S VIEW ON ITS POTENTIAL AND LIMITATIONS IN MONITORING RESISTANCE AND DETECTING MINIMAL RESIDUAL DISEASE**
A. Ryška (Hradec Králové)

## Thursday 10 September

13:45 75. **IMPLEMENTATION OF NGS IN CLINICAL ROUTINE: CURRENT CHALLENGES IN THE INTERPRETATION OF RESULTS AND STANDARDIZATION OF REPORTING FOR CLINICAL ONCOLOGISTS**
O. Slabý (Brno)

14:00 76. **THE TURBULENT FUTURE OF KRAS INHIBITION**
S. John (Hradec Králové)

14:15 77. **GENESIS PLATFORM: OUTCOMES OF THERAPY INDICATION BASED ON GENOMIC PROFILING IN OVER 2,600 PATIENTS AND THE TRANSITION TO THE GENESIS PRO ACADEMIC TRIAL**
P. Grell, M. Eid, L. Křížová, M. Kysela, B. Mohelníková Duchoňová, B. Melichar, M. Vočka, R. Lohynská, R. Soumarová, R. Lordick Obermannová (Brno, Prague, Olomouc)

14:30 78. **EARLIER ACCESS TO TARGETED AND PHASE I/II THERAPIES: HOW GERMANY'S REIMBURSED GENOME SEQUENCING MODEL PROJECT RESHAPES THE CANCER TREATMENT SEQUENCE**
E. Rohleder (Berlin)

14:45 79. **PHARMACOECONOMICS OF INNOVATIVE MOLECULES**
J. Fínek (Pilsen)

14:55 Discussion

15:00 Break

**15:10–16:40 IBOD BREAKING NEWS 2026 ***
Moderators: F. Lordick, D. Cibula
Chairs: N. Harbeck, J. Kucharz, E. Fontana, A. von Deimling, M. Casas Ovejero (Munich, Warsaw, London, Heidelberg)

15:10 80. **CURRENT AND EMERGING STRATEGIES IN HER2-POSITIVE BREAST CANCER MANAGEMENT**
N. Harbeck (Mnichov)

15:25 81. **WHAT CAN BE CONSIDERED REVOLUTIONARY IN GYNECOLOGICAL ONCOLOGY OVER THE LAST 50 YEARS?**
D. Cibula (Prague)

15:40 82. **RECENT ADVANCES IN COLORECTAL CANCER TREATMENT**
E. Fontana (London)

15:55 83. **BEYOND ADJUVANT THERAPY: MANAGING PROGRESSION TO METASTATIC RCC**
J. Kucharz (Warsaw)

16:10 84. **AI ASSISTED BRAIN TUMOR DIAGNOSTICS ON FFPE AND INTRAOPERATIVE HE SECTIONS**
A. von Deimling (Heidelberg)

16:25 85. **REPORTING TUMOR RESPONSE IN THE AGE OF AI**
M. Casas Ovejero (Heidelberg)

16:40 Coffee break

# Friday 11 September

**08:00–09:30** **IBOD CANCER SURVIVORSHIP – LIFE AFTER CANCER ***

Moderators: M. Svoboda, L. Dušek, L. Pavčíková

Chairs: F. Lordick, M. Balcerek, L. Predel (Leipzig)

08:00 208. **CANCER SURVIVORSHIP IN THE CZECH REPUBLIC: STATISTICAL INSIGHTS INTO SOCIAL REINTEGRATION AND QUALITY OF LIFE**
L. Dušek (Prague)

08:20 209. **CANCER SURVIVORSHIP: FROM TREATMENT COMPLETION TO LONG-TERM WELLBEING**
M. Balcerek (Leipzig)

08:40 210. **CANCER PREVENTION IN THE WORK SETTING: THE ONCONNECT PROJECT**
L. Predel (Leipzig)

09:00 211. **SURVIVORSHIP CARE IN CLINICAL PRACTICE: EXPERIENCE FROM A PILOT PROGRAM AT MMCI**
L. Pavčíková (Brno)

09:20 Discussion

09:30 Coffee break

**09:50–11:20** **EDUCATIONAL SESSION BREAST CANCER ***

Moderators: M. Holánek, K. Petráková

Chairs: R. Bartsch, Z. Bielčiková (Vienna, Prague)

09:50 **OPENING**

09:55 212. **CURRENT ROLE OF ANTIBODY–DRUG CONJUGATES IN THE TREATMENT OF BREAST CANCER**
Z. Bielčiková (Prague)

10:15 213. **CNS METASTASES IN BREAST CANCER: A NEW ERA OF SYSTEMIC THERAPY**
R. Bartsch (Vienna)

10:35 214. **BREAST CANCER ACROSS SUBTYPES: CASE STUDIES AND MODEL SCENARIOS FROM CLINICAL PRACTICE**
M. Holánek (Brno)

10:55 215. **MODERATED PANEL DISCUSSION: ANTIBODY–DRUG CONJUGATES, CNS METASTASES AND PRACTICAL CLINICAL DECISION-MAKING**
R. Bartsch, Z. Bielčiková, K. Petráková, M. Holánek (Vienna, Prague, Brno)

11:20 Break

**11:30–13:00** **IBOD CASE REPORTS**

Moderators: T. Sokop, A. Pirshtuk

Chairs: T. Büchler, M. Vočka, M. Holánek (Prague, Brno)

11:30 **OPENING**

11:35 216. **HILAR CHOLANGIOCARCINOMA WITH BRCA2 MUTATION: NAVIGATING TREATMENT DECISIONS IN A COMPLEX CLINICAL SETTING**
A. Pirshtuk (Prague)

11:50 217. **IMUNNE CHECKPOINT INHIBITORS IN METASTATIC COLORECTAL CARCINOMA**
B. Špánik (Bratislava)

*Simultaneous interpretation is provided in this session.

## Friday 11 September

| | | |
|---|---|---|
| 12:05 | 218. | **CLAUDIN 18.2-POSITIVE GASTRIC ADENOCARCINOMA WITH PERITONEAL METASTASIS**<br>M. Tepe (Leipzig) |
| 12:20 | 219. | **EFFECT OF IMMUNOTHERAPY IN TMB-HIGH METASTATIC LUMINAL BREAST CANCER: A CASE REPORT**<br>M. Iviczeová (Brno) |
| 12:35 | 220. | **PREDICTORS OF DISEASE RECURRENCE IN LOW GRADE SOFT TISSUE SARCOMA: A SINGLE INSTITUTION COHORT STUDY**<br>K. Helbig (Warsaw) |
| 12:50 | | Discussion |
| 13:00 | | Lunch |

## Prof. Rupert Bartsch, MD

Medical University of Vienna, Austria

**CNS METASTASES IN BREAST CANCER: A NEW ERA OF SYSTEMIC THERAPY**

**Friday, 11 September 2026, 10:15 a.m., J. Bakeš Hall**

Rupert Bartsch, MD, is a Professor of Medicine at the Medical University of Vienna, Austria, where he serves as Director of the Breast Cancer Programme at the Department of Oncology and Consultant Medical Oncologist at the Clinical Division of Oncology. He previously coordinated the interdisciplinary Breast Centre at Elisabethinen Hospital in Linz and served as Vice President for Medicine and Research at the German Breast Group in Neu-Isenburg, Germany.

In addition to his longstanding research activities with the Austrian Breast and Colorectal Cancer Study Group (ABCSG), his clinical and scientific work focuses on breast cancer, central nervous system metastases, HER2-positive breast cancer, antibody-drug conjugates and the development of innovative systemic treatment strategies.

Dr. Bartsch has authored or co-authored more than 200 peer-reviewed scientific publications, including papers in Nature Medicine, The New England Journal of Medicine, The Lancet Oncology, Journal of Clinical Oncology, Annals of Oncology and other leading oncology journals. His publications have been cited extensively and have contributed to the development of evidence-based treatment recommendations for breast cancer.

He is an active member of several international professional organizations, including the European Society for Medical Oncology (ESMO), where he serves on the ESMO Breast Cancer Faculty, the Breast International Group (BIG) Brain Metastases Task Force.

**Selected recent publications:**

1. de Azambuja E, Barrios CH, Bartsch R, Curigliano G, Dent R, Gennari A, Loi S ... Harbeck N; ESMO Guidelines Committee. Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2026; S0923-7534(26)00902-6.

2. Thill M, Müller V, Fehm T, Albert US, Banys-Paluchowski M, Bartsch R et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2026. Breast Care (Basel) 2026; 88: 104837.

3. Decaminada A, Sunder-Plassmann R, Ho WK, Muhr D, Starzer AM, Berghoff AS, Bartsch R, Singer CF, kConFab Investigators, Tan YY. Gene-Specific Outcomes After Central Nervous System Metastases in Germline BRCA1- and BRCA2-Associated Breast Cancer. Cancers (Basel) 2026; 18(8): 1240.

4. Sanchez-Bayona R, Anders C, Bartsch R, Cameron DA, Ciruelos EM, Criscitiello C, Duhoux FP... Harbeck N. Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidence. Breast 2026; 88: 104837.

5. Bartsch R, Marhold M, Garde-Noguera J, Gion M, Ruiz-Borrego M, Greil R, Valero M, Llombart-Cussac A, García-Mosquera JJ, Arumi M, et al. Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2025; 26(11): 1454–1466.

## Prof. Andrés Cervantes, MD, PhD

University Hospital in Valencia, Spain

**FIFTY YEARS OF PROGRESS IN ONCOLOGY:**
**FROM EMPIRICAL TREATMENT STRATEGIES TO PRECISION MEDICINE**

**Wednesday, 9 September 2026, 2:00 p.m., J. Bakeš Hall**

Andrés Cervantes, MD, PhD, is a Professor of Medicine and serves as Head of the Department of Medical Oncology at the University Hospital in Valencia, Spain. He is also Scientific director of the Institute of Health Research INCLIVA, where he coordinates cancer research activities.

His clinical and research interests focus mainly on gastrointestinal cancers, early clinical trials, development of new anticancer drugs, precision oncology and translational research. He leads research programmes investigating liquid biopsy approaches for detection of minimal residual disease in colorectal cancer and the use of patient-derived models, including organoid platforms, to improve treatment strategies.

Prof. Cervantes has authored more than 600 research articles and educational papers published in peer-reviewed journals. He is particularly involved in training new oncologists and young clinical researchers to facilitate the connection between science and knowledge in health care. He has supervised more than 20 PhD theses. He has been included in the Clarivate Analytics list of most cited researchers of the year 2021–2023.

He served as President of the European Society for Medical Oncology (ESMO) during 2023–2024 and subsequently as immediate Past-President (2025–2026). During his leadership of ESMO, he focused on improving access to cancer care, strengthening oncology education and promoting international scientific collaboration. He has been recently recognized as a member of Academia Europea.

**Selected recent publications:**

1. Camblor DG, Martínez-Castedo B, Martín-Arana J, Gimeno-Valiente F, García-Micó B ... Cervantes A et al. Clinical performance of tumor-informed versus tumor-agnostic ctDNA assays for colorectal cancer recurrence: A systematic review and diagnostic accuracy meta-analysis. Cancer Treat Rev 2026; 142: 103066.

2. Martín-Arana J, Gimeno-Valiente F, Henriksen TV, García-Micó B, Martínez-Castedo B ... Cervantes A et al. Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancer. Nat Cancer 2025; 6(6): 1000–1016.

3. Airoldi M, Roselló S, Tarazona N, Huerta M, Pérez-Santiago L, Fleitas T, Pla-Martí V, Puccini A, Roda D, Cervantes A. Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life. Cancer Treat Rev 2025; 140: 103015.

4. Hofheinz RD, Fokas E, Benhaim L, Price TJ, Arnold D, Beets-Tan R, Guren MG, Hospers GAP, Lonardi S, Nagtegaal ID, Perez RO, Cervantes A, Martinelli E; ESMO Guidelines Committee. Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2025; 36(9): 1007–1024.

5. Seguí V, Carbonell-Asins JA, Martín-Arana J, García-Bartolomé M, Grimalt N ... Cervantes A et al. Enhancing precision oncology: the role of molecular tumor boards in early identification and targeted treatment of ESCAT II-III alterations. ESMO Open 2025; 10(10): 105771.

## Elisa Fontana, MD, PhD

Sarah Cannon Research Institute in London, United Kingdom

**RECENT ADVANCES IN COLORECTAL CANCER TREATMENT**

**Thursday, 10 September 2026, 3:40 p.m., J. Bakeš Hall**

Elisa Fontana, MD, PhD, is the Hospital Medical Director of the Sarah Cannon Research Institute in London, UK (part of HCA International and ESMO Designated Centre of Oncology and Palliative Care). She is Principal Investigator for over 50 first-in-humans to late phase clinical trials and oversees a portfolio of more than 100 active clinical trials and translational studies.

She graduated from the University of Parma, Italy in 2008 and completed her specialisation in Medical Oncology in 2014. She worked as sub-investigator in the gastrointestinal and drug development clinical trial units at The Royal Marsden Hospital, UK (2014–2019). She was awarded a PhD in colorectal cancer and biomarker assays development at the University of London, Institute of Cancer Research in 2019; she received the Chairman's Prize for outstanding PhD. She successfully completed an entrepreneurial training programme for early career researchers aiming to translate research into clinical practice. She served as co-Chair of the Adolescent and Young Adult Gastrointestinal Cancer Task Force at the European Organisation for Research and Treatment of Cancer (EORTC) (2019–2020) and as secretary of the EORTC Gastrointestinal Tract cancer group (2021–2024 mandate). She served as faculty in multiple ESMO Advanced Courses on Antibody-Drug Conjugates and Precision Oncology.

She is current member of the ASCO Scientific Programme Committee for Colorectal and Anal cancer (2025–2027 mandate). She has received multiple academic funding as lead applicant and over 10 ESMO and ASCO Merit Awards for conference presentations; she has published over 150 peer-reviewed articles, abstracts and book chapters.

**Selected recent publications:**

1. Serrano-Serrano ML, Godfried Sie C, Bechter O, Pretelli G, Vieito M, Fontana E et al. Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer. Cancer Res Commun 2026; 6(6): 1435–1446.

2. Bregni G, Leurquin B, Giasafaki P, Takemura N, Kokudo N ... Fontana E et al. Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysis. Eur J Cancer 2025; 231: 116092.

3. Acha-Sagredo A, Andrei P, Clayton K, Taggart E, Antoniotti C, Woodman CA, Afrache H, Fourny C, Armero M, Moinudeen HK, Green M, Bhardwaj N, Fontana E, et al. A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer. Cancer Cell 2025; 43(2): 292–307.e7.

4. Hecht JR, Park YS, Tabernero J, Lee MA, Lee S, Virgili AC, Van den Eynde M, Fontana E et al.; STELLAR-303 study investigators. Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial. Lancet 2025; 406(10517): 2360–2370.

5. Silverman IM, Schonhoft JD, Herzberg B, Yablonovitch A, Lagow E, Fiaux PC, Safabakhsh P, Sethuraman S, Ulanet D, Yang J, Kim I, Basciano P, Fontana E et al. Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response-Deficient Tumors. Clin Cancer Res 2025; 31(19): 4136–4149.

## Prof. Nadia Harbeck, MD, PhD

Center for Hereditary Breast and Ovarian Cancer, LMU University Hospital, Munich, Germany

**CURRENT AND EMERGING STRATEGIES IN HER2-POSITIVE BREAST CANCER MANAGEMENT**

**Thursday, 10 September 2026, 3:10 p.m., J. Bakeš Hall**

Nadia Harbeck, MD, PhD, is Director of the Breast Center, the Center for Hereditary Breast and Ovarian Cancer, and holds the chair for Conservative Oncology at the Dept. of OB&GYN, LMU University Hospital, Munich. She obtained her specialist degree (OB&GYN) at the  echnical University of Munich and her medical degree from the Ludwig-Maximilians-University of Munich.

Professor Harbeck is the current chair of the ESMO Breast Cancer Faculty; she served as ESMO Director of Education and member of the ESMO Executive Board (2023–2025) as well as Subject Editor of the ESMO Breast Cancer Guidelines (2022–2025). She was member of the ASCO Annual Meeting Educational Committee (2022–2025). She is member of the expert panel issuing the German AGO recommendations for breast cancer therapy. She is co-director of the West German Study Group. From 2009–2015, she served on the EORTC Executive Board as chair of the Translational Research Division. Professor Harbeck is principal investigator or steering committee member of numerous breast cancer trials, particularly with novel targeted compounds and individualized treatment strategies. She has a strong interest in eHealth and is co-developer of CANKADO, an international digital patient diary.

Prof. Harbeck is one of the most frequently cited clinical researchers worldwide. She has authored more than 780 papers in peer-reviewed journals (h-index 115) and is coordinating editor-in-chief of Breast Care (Karger Publishers). She co-directed the annual ESMO AACR EORTC Methods in Clinical Cancer Research Workshop from 20218–2019 and 2022–2024 and is a panel member of several international breast cancer consensus conferences.

In 2025, Prof. Harbeck received the Bavarian Order of Merit from the Governor of Bavaria, Germany. She is Adjunct Professor of the University of Vienna, Austria, and recipient of the 2023 German Cancer Award and the 2020 ESMO Lifetime Achievement Award. She received several additional recognitions of her clinical and translational research such as the 2021 UPO Award for Women in Academy and Research, the 2015 Bavarian Cancer Patient Award, the 2012 Claudia von Schilling Award, the 2008 EBCC Award, the 2002 AGO Schmidt-Matthiesen Award, a 2001 AACR Award, and the 2001 ASCO Fellowship Merit Award for the highest ranking abstract.

**Selected recent publications:**

1. Thill M, Müller V, Fehm T, Albert US, Banys-Paluchowski M, Bartsch R ... Harbeck N et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2026. Breast Care (Basel). 2026 Mar 20. Epub ahead of print.

2. Park-Simon TW, Müller V, Albert US, Banys-Paluchowski M, Bartsch R ... Harbeck N et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2026. Breast Care (Basel). 2026 Mar 12. Epub ahead of print.

3. Loi S, Salgado R, Curigliano G, Romero Díaz RI, Delaloge S, Rojas García CI, Kok M, Saura C, Harbeck N et al. Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. Nat Med. 2025; 31(2): 433–441.

## Assoc. Prof. Jakub Kucharz, MD, PhD

Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

**BEYOND ADJUVANT THERAPY: MANAGING PROGRESSION TO METASTATIC RCC**

**Thursday, 10 September 2026, 3:55 p.m., J. Bakeš Hall**

Dr. Kucharz is associate professor of medical oncology at Maria Sklodowska-Curie National Research Institute of Oncology, where he also serves as head of the Medical Oncology Unit within the Department of Genitourinary Oncology. He graduated Jagiellonian University Medical College in Kraków in 2009, obtained his PhD in 2014 and completed his habilitation in 2019.

Dr. Kucharz is board-certified medical oncologist focused on genitourinary oncology and supportive care. His clinical interests include renal cell carcinoma, urothelial cancer, prostate cancer, testicular germ cell tumours, rare genitourinary malignancies, management of oncological emergencies, treatment of elderly and medically complex patients, and supportive care in oncology.

He is General Secretary of the Executive Board of Polish Society of Clinical Oncology and secretary of the Supportive Care Section of Polish Society of Clinical Oncology. He is also the member of European Society for Clinical Oncology.

Dr. Kucharz research interests are focused on prognostic and predictive factors for targeted therapies and immunotherapy, adverse events management and treatment of critically-ill germ cell tumor patients.

He has authored and co-authored more than 90 peer-reviewed scientific publications and has contributed to national clinical practice guidelines on genitourinary malignancies and supportive care developed by the Polish Society of Clinical Oncology

Dr. Kucharz serves as peer reviewer for several international oncology journals, and is a member of the editorial boards of BMC Medicine (Oncology Section), Frontiers in Oncology (Genitourinary Oncology Section), and Oncology in Clinical Practice).

**Selected recent publications:**

1. Maruzzo M, Poprach A, Buti S, Bamias A, Zakopoulou R, DE Giorgi U, Kucharz J et al. Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study). Minerva Urol Nephrol 2026; 78(2): 210–221.

2. Molina-Cerrillo J, Roviello G, Bourlon MT, Studentova H, Fiala O, Cerbone L, Kucharz J et al. Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study). Int J Cancer 2026; 158(5): 1396–1405.

3. Kucharz J, Poprach A, Sikora-Kupis B, Darewicz M, Domański P, Bezděková M, Koloušková I, Kolaríková E, Kopecky J, Studentova H, Fiala O, Richter I, Lacek M, Buchler T, Pinto A. Cabozantinib in the First-Line Treatment of Patients With Metastatic Renal Cell Carcinoma, Real-World Data From the Czech Republic and Poland: ICARO-RC Project. Clin Genitourin Cancer. 2025; 23(4): 102382.

4. Kopp RM, Massari F, Grande E, Schieber TJ, Ürün Y, Kopecký J, Molina-Cerrillo J, Basso U, Kucharz J, et al. Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study. Cancer Immunol Immunother 2025; 74(12): 374.

5. Bourlon MT, Galli L, Grande E, Park SH, Melichar B, Schieber TJ, Juan-Fita MJ, Ürün Y, Molina-Cerrillo J, Alonso-Gordoa T, De Giorgi U, Kucharz J, et al. Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study. Front Oncol 2025; 15: 1605282.

## Prof. Cord Langner, MD

Diagnostic and Research Institute of Pathology, Medical University of Graz, Austria

**PREDICTIVE BIOMARKERS IN GI ONCOLOGY: FROM PATHOLOGY TO PERSONALISED TREATMENT**

**Thursday, 10 September 2026, 9:50 a.m., J. Bakeš Hall**

Prof. Cord Langner, MD, graduated from the University of Bonn, Germany. Afterwards, he completed a pathology residency program at Klinikum Kassel, Germany. Since the year 2000, he works as a board-certified pathologist at the Diagnostic and Research Institute of Pathology, Medical University of Graz, Austria, where he specializes in gastrointestinal pathology, hepatobiliary pathology and molecular pathology.

Dr. Langner has published more than 250 original peer-reviewed papers, which were well cited. His Hirsch Index is 54 (ISI Web of Knowledge). In addition, he looks back to more than 500 invited lectures on the occasion of national and international meetings.

Dr. Langner served as board member in the Austrian, German and European Societies of Pathology and chaired the working group of digestive disease of the European Society of Pathology (ESP).

He is currently the director of the Advanced Training Center of Gastrointestinal Pathology of the ESP.

He is Associate Editor of Virchows Archiv and previously served as Associate Editor of Histopathology. In addition, he founded the European Network of Gastrointestinal Pathology (ENGIP), an international collaborative network established to promote education, research and guideline dissemination in gastrointestinal pathology, and co-founded the Pannonian Working Group of Pathology, which brings together pathologists from six Central European countries.

His research interests focus on gastrointestinal neoplasia, colorectal cancer pathology, inflammatory bowel disease, Barrett's oesophagus, tumour budding, prognostic and predictive biomarkers, and the implementation of molecular pathology in routine diagnostic practice.

**Selected recent publications:**

1. Henzinger H, Brown I, Gill AJ, Slavik T, Zamboni G, Langner C. Chronic ulcerative oesophagitis rich in IgG4-positive plasma cells - a distinct clinicopathological entity. Histopathology 2026; 89(1): 47–57.
2. Patil A, Jiezhen TL, Kosiorek H, Brown IS, Carneiro F, Gill AJ, Kumarasinghe PM, Kushima R, Sheahan K, Shepherd NA, Slavik T, Srivastava A, Lauwers GY, Langner C, Pai RK. An international inter-rater agreement study in the challenging diagnosis of squamous dysplasia of the oesophagus. Histopathology 2025; 87(4): 573–583.
3. Coady LC, Sheahan K, Brown IS, Carneiro F, Gill AJ, Kumarasinghe P, Kushima R, Lauwers GY, Pai RK, Shepherd NA, Slavik T, Srivastava A, Langner C. Esophageal lymphocytosis: exploring the knowns and unknowns of this pattern of esophageal injury. Expert Rev Gastroenterol Hepatol 2024; 18(9): 529–539.
4. Köhler J, Hammerl R, Mayer DM, Fessler J, Langner C. Colitis associated with persistent drug-induced immune dysregulation Virchows Arch 2024; 485(6): 1151–1155.
5. El-Mahrouk M, El-Shabrawi A, Langner C, Hau HM, Sucher R. Transduodenal resection of a large papillary tumor by means of intraoperative cholangioscopy. Int J Surg Case Rep 2024; 124: 110364.

## Elena Rohleder, MD

Comprehensive Cancer Center, Charité University Hospital Berlin, Germany

**EARLIER ACCESS TO TARGETED AND PHASE I/II THERAPIES: HOW GERMANY'S REIMBURSED GENOME SEQUENCING MODEL PROJECT RESHAPES THE CANCER TREATMENT SEQUENCE**

**Thursday, 10 September 2026, 2:30 p.m., J. Bakeš Hall**

Elena Rohleder is a board-certified specialist in Internal Medicine currently completing advanced subspecialty training in Hematology and Medical Oncology at Charité – Universitätsmedizin Berlin, where she works at the Comprehensive Cancer Center. Her clinical practice encompasses the diagnosis and treatment of patients with hematologic malignancies and solid tumors in both inpatient and outpatient settings. She has extensive experience in planning and supervising systemic anticancer therapies, including chemotherapy, immunotherapy, targeted therapies, and palliative care. Her work also includes cytological and flow cytometric diagnostics, interdisciplinary tumor boards, second-opinion consultations, and the conduct of Phase I–III clinical trials.

Dr. Rohleder studied Human Medicine at Johannes Gutenberg University Mainz and received her Doctor of Medicine degree in 2017. Her doctoral thesis investigated the regulation and function of arginine transporters in human B lymphocytes, reflecting her early interest in tumor biology and immunology. She subsequently began her residency in Internal Medicine at Charité Berlin, completing comprehensive clinical training in hematology and oncology as well as emergency medicine, intensive care, gastroenterology, and nephrology. She obtained board certification in Internal Medicine in 2024 and has continued her specialist training in Hematology and Medical Oncology.

Alongside her clinical work, Dr. Rohleder has maintained a strong commitment to translational cancer research. Between 2019 and 2021, she worked in the research group of Professor Ulrich Keller, investigating the role of SUMOylation in the pathogenesis of malignant lymphomas. This work contributed to high-impact publications in Nature Communications and the Journal of Clinical Investigation, advancing the understanding of molecular mechanisms involved in lymphoma development and tumor immune evasion. She has also co-authored clinical research on prognostic factors and treatment strategies in lymphoma, reflecting her interest in bridging laboratory discoveries with patient care.

Dr. Rohleder is an active member of several leading professional societies, including the German Society of Hematology and Medical Oncology (DGHO), where she participates in the Precision Oncology Working Group, the European Society for Medical Oncology (ESMO), the Working Group for Medical Oncology (AIO), and the German Cancer Society (DKG). Her professional interests focus on precision oncology, lymphoma biology, clinical trials, and the development of personalized treatment strategies aimed at improving outcomes for patients with cancer.

## Prof. Andreas von Deimling, MD

Heidelberg University Hospital, German Cancer Research Center, Heidelberg, Germany

**AI ASSISTED BRAIN TUMOR DIAGNOSTICS ON FFPE AND INTRAOPERATIVE HE SECTIONS**

**Thursday, 10 September 2026, 4:10 p.m., J. Bakeš Hall**

Prof. Andreas von Deimling, MD, is a Director of the Department of Neuropathology at Heidelberg University Hospital and Head of the Clinical Cooperation Unit Neuropathology at the German Cancer Research Center in Heidelberg. He studied medicine at the University of Freiburg. Following residency training in neuropathology at the University of Zurich and the University of Bonn, he completed a postdoctoral fellowship in neurogenetics at Massachusetts General Hospital and Harvard Medical School, Boston. He obtained board certification in Neuropathology and completed his habilitation at the University of Bonn in 1995.

Before joining Heidelberg in 2007, Prof. von Deimling served as Chair of Department of Neuropathology at Charité in Berlin. Since 2007, he has led one of Europe's leading centres for diagnostic and molecular neuropathology. His principal research interests include molecular genetics of brain tumours, glioma biology, tumour diagnostics, epigenetic biomarkers and translational neuro-oncology.

Prof. von Deimling has authored more than 500 peer-reviewed scientific publications and is among the world's most highly cited researchers in neuropathology and neuro-oncology. His work has had a major impact on the molecular classification of diffuse gliomas and other central nervous system tumours, leading to the development of mutation-specific antibodies and other diagnostic approaches.

His scientific achievements have been recognized by numerous prestigious awards, including the German Cancer Award for Translational Research, the Fred W. Stewart Award of Memorial Sloan Kettering Cancer Center, the Dorothy Russell Medal of the British Neuropathological Society, the Neuro-Oncology Scientific Award of the American Academy of Neurology, the International Prize for Translational Neuroscience, and the Alfons Maria Jakob Award of the German Society of Neuropathology and Neuroanatomy.

**Selected recent publications:**

1. Sill M, Schrimpf D, Patel A, Sturm D, Jäger N, Sievers P, Schweizer L, Banan R, Reuss D, Suwala A, von Deimling A et al. Advancing CNS tumor diagnostics with expanded DNA methylation-based classification. Cancer Cell 2026; 44(2): 340–354.e2.

2. Jin D, Shmatko A, Patel A, Rutz S, Friedrich L, Banan R, Rahmanzade R, Sievers P, Hamelmann S, Schrimpf D, von Deimling A et al. Hetairos is a histology-based artificial intelligence model for predicting central nervous system tumor methylation subtypes. Nat Cancer 2026; 7(6): 884–898.

3. Patel A, Göbel K, Ille S, Hinz F, Schoebe N, Bogumil H, Meyer J, Brehm M, Kardo H, Schrimpf D, von Deimling A et al. Prospective, multicenter validation of a platform for rapid molecular profiling of central nervous system tumors. Nat Med 2025; 31(5): 1567–1577.

4. Benfatto S, Sill M, Jones DTW, Pfister SM, Sahm F, von Deimling A, Capper D, Hovestadt V. Explainable artificial intelligence of DNA methylation-based brain tumor diagnostics. Nat Commun 2025; 16(1): 1787.

5. Ritter M, Blume C, Tang Y, Patel A, Patel B, Berghaus N, Kada Benotmane J, Kueckelhaus J, Yabo Y, Zhang J, von Deimling A, et al. Spatially resolved transcriptomics and graph-based deep learning improve accuracy of routine CNS tumor diagnostics. Nat Cancer 2025; 6(2): 292–306.

## Dr. Elizabeth Smyth

Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

**FUTURE DIRECTIONS IN PERSONALISED NEOADJUVANT TREATMENT OF OESOPHAGOGASTRIC ADENOCARCINOMA**

**Thursday, 10 September 2026, 10:05 a.m., J. Bakeš Hall**

Dr. Elizabeth Smyth is a Medical Oncologist and Gastrointestinal Oncology Lead in Oxford. She also serves as Clinical Lead for the Oxford Clinical Trials Office and Deputy Lead for the Oxford Experimental Cancer Medicine Centre. Her work focuses on improving patient outcomes through high-quality clinical trials, translational research, and international collaboration.

Having trained in Ireland, Australia, the USA, and the UK, she brings a global perspective to clinical practice and research. Fellowships at Memorial Sloan Kettering Cancer Center and the Royal Marsden established her focus on biomarker-driven, personalised cancer treatment.

Dr. Smyth leads several national and international investigator-initiated studies, including DECIPHER, ELEVATE, and VESTIGE, evaluating immunotherapy and targeted therapies for resectable and advanced oesophagogastric cancers. She has held leadership roles in trials supported by EORTC, Cancer Research UK, and international industry partners. She holds an MSc in Clinical Trials and an MD (Res) in translational oncology and has authored more than 200 publications, including papers in Annals of Oncology, The Lancet, Journal of Clinical Oncology, JAMA Oncology, Gut, Science, and Cancer Cell.

Education and mentorship are central to her work. Since 2017, she has been a member of the ESMO Upper GI Faculty, regularly chairing and speaking at ESMO educational programmes across Europe, Asia, Africa, and Latin America. She serves on the scientific organising committees for ESMO, ASCO, ESMO Asia, and ESMO GI meetings. An ESMO mentor since the programme's inception, she has mentored fellows from Europe and around the world.

Dr. Smyth currently serves as Chair of the ESMO Guidelines Committee and is an ex-officio member of the ESMO Educational Committee and Council. She previously chaired the ESMO National Societies Committee and the OncologyPRO Working Group. She is also Chair of the EORTC Gastrointestinal Trials Group and National Specialty Co-Lead (Oncology) for the UK NIHR Research Delivery Network, supporting research infrastructure and international collaboration.

**Selected recent publications:**

1. Puhr HC, Borges FC, Monard L, De la Fouchardière C, Silva JP, Smyth EC, Lacombe D, van Laarhoven HW. Pragmatism in academic gastrointestinal cancer clinical trials: An analysis of trials conducted by the EORTC gastrointestinal tract cancer group and the unicancer gastrointestinal group. Eur J Cancer 2026; 241: 116771.

2. Zhu H, Lordick F, Janjigian YY, Rha SY, Nilsson M, Shitara K, Owen R, Zhang Z, Smyth EC. Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons. Nat Rev Clin Oncol 2026. Epub ahead of print.

3. Sundar R, Nakayama I, Markar SR, Shitara K, van Laarhoven HWM, Janjigian YY, Smyth EC. Gastric cancer. Lancet. 2025;405(10494): 2087-2102.

4. de la Fouchardière C, Cammarota A, Svrcek M, Alsina M, Fleitas-Kanonnikoff T, Lordick F, Obermannová R, Wagner AD, Yap WT, Enea D, Petrillo A, Smyth EC. How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force. Cancer Treat Rev. 2025;134:102890.

5. Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E ... Smyth EC et al; MATTERHORN Investigators. Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer. N Engl J Med 2025; 393(3): 217–230.

# OTHER IMPORTANT FOREIGN SPEAKERS

## Prof. Florian Lordick, MD, PhD

University Cancer Center Leipzig, Leipzig University Medical Center, Leipzig, Germany

**Moderator: IBOD Future Directions in Personalized Neoadjuvant Treatment / IBOD Breaking News 2026 / IBOD Cancer Survivorship – Life after Cancer**

**Thursday, 10 September 2026, 9:50 a.m. and 3.10 p.m., J. Bakeš Hall**

**Friday, 11 September 2026, 8:00 a.m., J. Bakeš Hall**

## Miriam Casas Ovejero

Mint Medical, Heidelberg, Germany

**REPORTING TUMOR RESPONSE IN THE AGE OF AI**

**Thursday, 10 September 2026, 4.25 p.m., J. Bakeš Hall**

## Magdalena Balcerek, MD

University Cancer Center Leipzig, Leipzig University

**CANCER SURVIVORSHIP: FROM TREATMENT COMPLETION TO LONG-TERM WELLBEING**

**Friday, 11 September 2026, 8:20 a.m., J. Bakeš Hall**

## Laura Predel, MD

University Cancer Center Leipzig, Leipzig University

**CANCER PREVENTION IN THE WORK SETTING: THE ONCONNECT PROJECT**

**Friday, 11 September 2026, 8:40 a.m., J. Bakeš Hall**

# DIAGNOSTIC AND TREATMENT CENTRES IN MMCI

Every year, almost **5 000 newly diagnosed cancer patients** start treatment at MMCI. We perform approximately 5 500 surgeries, including robotic-assisted (2 da Vinci surgical systems), more than 8 000 patients is treated by anticancer drugs and 3 500 is treated by radiotherapy. MMCI has **23 diagnostic and treatment centres** that focus on various types of solid tumors, or specific treatment modalities requiring interdisciplinary collaboration. In addition to these, MMCI operates **Centre for Innovative and Supportive Care** and unique **Cancer Prevention Centre**.

Our patients have access to the most innovative diagnostics and cancer treatment. The principles of **personalized and precision oncology** are applied in surgical, radiation, and medical treatment of cancer. MMCI has had a molecular tumor board (MTB) since 2019, is the leader of the national MTB registry GENESIS and is a **partner site of PRIME-ROSE**, an international consortium focused on the precision use of cancer medicine. Together with the Institute of Nuclear Research (ÚJV Řež), we operate the **PET/Cyclotron Centre**, which includes a theranostic unit.

In cooperation with the institutional Patient Council, we have implemented the **Patient-Centered Cancer Care model and Survivorship program**. MMCI consistently achieves the highest rating, **„A+“**, in external patient satisfaction assessments of Czech hospitals.

**Breast Cancer Centre**

**Centres for Gastrointestinal tumors**
- Centre for Oesophageal and Gastric Cancer
- Colon Cancer Centre
- Centre for Liver and Biliary Tract Cancer
- Centre for Pancreatic Cancer

**Centres for Urologic tumors**
- Prostate Cancer Centre
- Kidney and Urinary Tract Cancer Centre
- Testicular Cancer Centre

**Centres for Gynecologic tumors**
- Centre for Ovarian, Tubal and Peritoneal Cancers
- Centre for Uterine, Cervical and Vulvar Cancers

**Centre for Lung and Pleural Cancer**

**Centre for Skin Cancer and Melanoma**

**Centre for Brain and Spinal Cord Tumours**

**Head and Neck Cancer Centre**

**Sarcoma centre**

**Centre for Neuroendocrine Tumours**

**Thyroid Cancer Centre**

**Centre for cancer of unknown primary and other rare malignancies**

**Centre for AYA cancer patients**

**Centre for Precision Oncology**

**Robotic Surgery Centre**

**Centre for Palliative Medicine and Pain Management**

**Centre for cytoreduction and regional chemotherapy**

Masaryk Memorial Cancer Institute

ECI Comprehensive Cancer Centre

EUnetCCC

# ABOUT THE MASARYK MEMORIAL CANCER INSTITUTE

Masaryk Memorial Cancer Institute (MMCI) is the largest cancer center in the Czech Republic, providing healthcare services, research, and education in the areas of prevention, diagnosis, and treatment of solid tumors. It is an institution working under the direct supervision of the Czech Ministry of Health. **MMCI is one of the two National Cancer Centres** (NCC) within the network of sixteen Czech Comprehensive Cancer Centres and is a **member of the Czech National Institute for Cancer Research**. As part of the NCC, MMCI collaborates closely with two university hospitals: St. Anne's UH and UH Brno. MMCI leads the regional South Moravian Oncology Network.

**We are an internationally recognized institute**, an accredited member of the Organisation of European Cancer Institutes (**OECI Comprehensive Cancer Centre**), and a full member of the European Reference Networks on rare adult solid cancers (EURACAN) and on genetic tumor risk syndromes (GENTURIS). The ESMO has granted MMCI the status of an „ESMO Designated Centre of Integrated Oncology and Palliative Care." We are part of the EUNetCCC initiative – **European network of Comprehensive Cancer Centres**, and are involved in numerous international research infrastructures and joint projects.

**MMCI is located in Brno**, the second largest city in the Czech Republic and the administrative city of the South Moravia region with more than 1.2 million inhabitants. Brno is home to nine universities and many research institutions. It is rich in historical landmarks and functionalist architecture. MMCI is located near the Augustinian Abbey, where **Gregor Johann Mendel**, the founder of genetics, served as abbot and made his famous discoveries.

**1 219** employees, of whom **138** hold a scientific degree
**220** inpatient beds / **8482** inpatient cases
**31** beds in **2** day care units / **32 009** treatment applications
**66** number of outpatient clinics / **575 479** outpatient treatments
**5 646** surgical procedures, including robotic surgeries
**570 312** radiotherapy procedures
**189** peer-reviewed publications
**135** clinical trials
**A+** rating from patients


**Masaryk Memorial Cancer Institute**

**Masarykův onkologický ústav**
Žlutý kopec 7,
656 53 Brno
Czech Republic

+420 543 13 4102/4103
direct@mou.cz

MOU.Brno mou.brno
@MOU_Brno